Clinical trial
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to…
NCT00407212 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00407212 |
|---|---|
| Title | A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | TCH346 (dibenz[b, f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) |
| Enrollment | 301 |
| Start date | Jan 1, 2002 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Dec 4, 2006 |
| Last update posted | Nov 23, 2011 |
| Countries | Brazil, Canada, France, Germany, Italy, Netherlands, Portugal, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: